Skip to main content
Erschienen in: World Journal of Urology 2/2014

01.04.2014 | Original Article

Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study

verfasst von: Francesco Cantiello, Antonio Cicione, Riccardo Autorino, Andrea Salonia, Alberto Briganti, Matteo Ferro, Renato De Domenico, Sisto Perdonà, Rocco Damiano

Erschienen in: World Journal of Urology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the pathological characteristics of patients with metabolic syndrome (MetS) undergoing radical cystectomy (RC) for urothelial bladder cancer (BCa).

Methods

We retrospectively analyzed 262 consecutive patients with muscle-invasive urothelial BCa or non-muscle-invasive urothelial BCa bacillus Calmette-Guerin refractory undergoing RC with standard pelvic lymphadenectomy. The patients were stratified into those with or without MetS, and a bivariate logistic regression analysis was done to assess MetS and, separately, each single MetS component as independent predictors of higher pathological stage as well as of the presence of lymph vascular invasion (LVI) and lymph node metastasis (LM).

Results

Metabolic syndrome was found in 36.3 % of patients. At logistic regression analysis, the presence of MetS did not predict the risk of both higher pathological stage and LVI and LM. Investigating the single components of MetS after adjusting for age, gender, and smoking, the risk of higher pathological stage increased with body mass index [BMI (OR 1.307, 95 % CI 1.098–1.555)], waist circumference (OR 1.414, 95 % CI 1.364–1.668), and blood hypertension (OR 2.326, 95 % CI 1.147–4.717). Higher BMI also predicted the presence of LVI (OR 1.432, 95 % CI 1.173–1.748) and LM (OR 1.202, 95 % CI 0.951–1.519), whereas HDL cholesterol was inversely associated with the risk of LVI and LM.

Conclusions

Metabolic syndrome does not represent an independent risk factor for worse pathological findings in BCa. Conversely, individual components of MetS could increase the risk of higher stage as well as LM.
Literatur
2.
Zurück zum Zitat Ninomiya JK, L’Italien G, Criqui MH et al (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109:42–46PubMedCrossRef Ninomiya JK, L’Italien G, Criqui MH et al (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109:42–46PubMedCrossRef
4.
Zurück zum Zitat Pollack MN (2007) Insulin, Insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86(suppl):820S–822S Pollack MN (2007) Insulin, Insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86(suppl):820S–822S
5.
Zurück zum Zitat Hsing AW, Sakoda LC, Chua AC (2007) Obesity, metabolic syndrome and prostate cancer. Am J Clin Nutr 86(suppl):843S–857S Hsing AW, Sakoda LC, Chua AC (2007) Obesity, metabolic syndrome and prostate cancer. Am J Clin Nutr 86(suppl):843S–857S
6.
Zurück zum Zitat De Nunzio C, Aronson W, Freedland SJ et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61:560–570PubMedCrossRef De Nunzio C, Aronson W, Freedland SJ et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61:560–570PubMedCrossRef
7.
8.
Zurück zum Zitat Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164:1094–1102PubMedCrossRef Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164:1094–1102PubMedCrossRef
9.
Zurück zum Zitat De Nunzio C, Freedland SJ, Miano R et al (2011) Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 71:1492–1498 De Nunzio C, Freedland SJ, Miano R et al (2011) Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 71:1492–1498
11.
Zurück zum Zitat Jeon KP, Jeong TY, Lee SY et al (2012) Prostate cancer in patients with metabolic syndrome is associated with low grade gleason score when diagnosed on biopsy. Korean J Urol 53:593–597PubMedCentralPubMedCrossRef Jeon KP, Jeong TY, Lee SY et al (2012) Prostate cancer in patients with metabolic syndrome is associated with low grade gleason score when diagnosed on biopsy. Korean J Urol 53:593–597PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Haggstrom C, Stock T, Rapp K et al (2011) Metabolic syndrome and risk of bladder cancer: a prospective cohort study in the metabolic syndrome and cancer project (Me–Can). Int J Cancer 128:1890–1898PubMedCrossRef Haggstrom C, Stock T, Rapp K et al (2011) Metabolic syndrome and risk of bladder cancer: a prospective cohort study in the metabolic syndrome and cancer project (Me–Can). Int J Cancer 128:1890–1898PubMedCrossRef
13.
Zurück zum Zitat Koebnick C, Michaud D, Moore SC et al (2008) Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 17:1214–1221PubMedCrossRef Koebnick C, Michaud D, Moore SC et al (2008) Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 17:1214–1221PubMedCrossRef
14.
Zurück zum Zitat Holick CN, Giovannucci EL, Stampfer MJ et al (2007) Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 120:140–146PubMedCrossRef Holick CN, Giovannucci EL, Stampfer MJ et al (2007) Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 120:140–146PubMedCrossRef
15.
Zurück zum Zitat Larsson SC, Orsini N, Brismar K et al (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819–2823PubMedCrossRef Larsson SC, Orsini N, Brismar K et al (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819–2823PubMedCrossRef
16.
Zurück zum Zitat Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non muscle invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008PubMedCrossRef Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non muscle invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008PubMedCrossRef
17.
Zurück zum Zitat Abol-Eneim H, Tilki D, Mosbah A et al (2011) Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol 60:572–577CrossRef Abol-Eneim H, Tilki D, Mosbah A et al (2011) Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol 60:572–577CrossRef
18.
Zurück zum Zitat Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412PubMedCrossRef Shariat SF, Svatek RS, Tilki D et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412PubMedCrossRef
20.
Zurück zum Zitat Cameron AJ, Shaw JE, Zimmet PZ (2004) The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33:351–375PubMedCrossRef Cameron AJ, Shaw JE, Zimmet PZ (2004) The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33:351–375PubMedCrossRef
21.
Zurück zum Zitat Miccoli R, Bianchi C, Odoguardi L et al (2005) Prevalence of metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 15:250–254PubMedCrossRef Miccoli R, Bianchi C, Odoguardi L et al (2005) Prevalence of metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 15:250–254PubMedCrossRef
22.
Zurück zum Zitat Wallner LP, Morgenstern H, McGree ME et al (2010) The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted county study. BJU Int 107:929–935PubMedCentralPubMedCrossRef Wallner LP, Morgenstern H, McGree ME et al (2010) The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted county study. BJU Int 107:929–935PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Chromecki TF, Cha EK, Fajkovic H et al (2012) Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int 61:818–825 Chromecki TF, Cha EK, Fajkovic H et al (2012) Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int 61:818–825
24.
Zurück zum Zitat May M, Herrmann E, Bolenz C et al (2011) Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 18:2018–2025PubMedCrossRef May M, Herrmann E, Bolenz C et al (2011) Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 18:2018–2025PubMedCrossRef
25.
Zurück zum Zitat Koppie TM, Vickers AJ, Vora K, Bochner BH (2006) Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 107:2368–2374PubMedCrossRef Koppie TM, Vickers AJ, Vora K, Bochner BH (2006) Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 107:2368–2374PubMedCrossRef
26.
Zurück zum Zitat Wright JL, Lin DW, Porter MP (2008) The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 112:2401–2408PubMedCrossRef Wright JL, Lin DW, Porter MP (2008) The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 112:2401–2408PubMedCrossRef
27.
Zurück zum Zitat Tamura T, Inagawa S, Hisakura K et al (2012) Evaluation of serum high density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol 27:1635–1640PubMedCrossRef Tamura T, Inagawa S, Hisakura K et al (2012) Evaluation of serum high density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol 27:1635–1640PubMedCrossRef
28.
Zurück zum Zitat Van Roekel EH, Cheng KK, James ND et al (2013) Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. Int J Cancer 133:446–454PubMedCrossRef Van Roekel EH, Cheng KK, James ND et al (2013) Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. Int J Cancer 133:446–454PubMedCrossRef
29.
Zurück zum Zitat Stocks T, Van Hemelrijck M, Manjer J et al (2012) Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 59:802–810PubMedCrossRef Stocks T, Van Hemelrijck M, Manjer J et al (2012) Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project. Hypertension 59:802–810PubMedCrossRef
30.
Zurück zum Zitat Capitanio U, Suardi N, Shariat SF et al (2009) Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int 103:1359–1362PubMedCrossRef Capitanio U, Suardi N, Shariat SF et al (2009) Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int 103:1359–1362PubMedCrossRef
Metadaten
Titel
Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study
verfasst von
Francesco Cantiello
Antonio Cicione
Riccardo Autorino
Andrea Salonia
Alberto Briganti
Matteo Ferro
Renato De Domenico
Sisto Perdonà
Rocco Damiano
Publikationsdatum
01.04.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 2/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-013-1147-7

Weitere Artikel der Ausgabe 2/2014

World Journal of Urology 2/2014 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.